Last reviewed · How we verify
intralesional propranolol injection
Intralesional propranolol injection blocks beta-adrenergic receptors within hemangioma tissue, reducing angiogenesis and promoting vascular regression.
Intralesional propranolol injection blocks beta-adrenergic receptors within hemangioma tissue, reducing angiogenesis and promoting vascular regression. Used for Infantile hemangioma (intralesional injection), Proliferating hemangiomas.
At a glance
| Generic name | intralesional propranolol injection |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Beta-adrenergic antagonist |
| Target | Beta-adrenergic receptors (non-selective) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Propranolol, a non-selective beta-blocker, when injected directly into hemangioma lesions, inhibits beta-adrenergic signaling that promotes endothelial cell proliferation and survival. This leads to decreased expression of pro-angiogenic factors like VEGF and FGF, resulting in apoptosis of hemangioma cells and gradual involution of the vascular lesion. The local injection approach delivers high drug concentrations directly to the target tissue while minimizing systemic exposure.
Approved indications
- Infantile hemangioma (intralesional injection)
- Proliferating hemangiomas
Common side effects
- Local injection site reactions (pain, erythema, edema)
- Transient hypotension
- Bradycardia
- Hypoglycemia
Key clinical trials
- Low-Dose Propranolol and Bleomycin for Infantile Hemangioma (IH) (NA)
- Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intralesional propranolol injection CI brief — competitive landscape report
- intralesional propranolol injection updates RSS · CI watch RSS
- Ain Shams University portfolio CI